Indium In 111 Satumomab Pendetide
Radiolabelled antibody imaging is the function of indium In-111 satumomab pendetide, which couples a tumour-directed antibody to an indium-111 label through a pendetide chelator. The antibody delivers the radionuclide to tumour cells, and gamma detection then reveals deposits of colorectal or ovarian cancer that may have spread beyond the primary site. Detection rather than treatment is the purpose: the emitted radiation is used for imaging, not for cytotoxic effect. The approach represents an early application of antibody targeting to nuclear medicine, preceding the therapeutic radioconjugates that followed. The product is classified as an antibody agent and reached the final phase of clinical development.
A radioactive imaging agent used to detect colorectal and ovarian cancer that may have spread in the body. It uses an antibody to carry a radioactive label to tumor cells for imaging.
Therapeutic Areas
Mechanism of Action
A murine monoclonal antibody against tumour-associated glycoprotein 72 (TAG-72), linked through the pendetide chelator to indium-111. The antibody localises to TAG-72-expressing colorectal and ovarian adenocarcinoma deposits, and the bound indium-111 emits the gamma photons that allow those deposits to be imaged.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
A murine monoclonal antibody against tumour-associated glycoprotein 72 (TAG-72), linked through the pendetide chelator to indium-111. The antibody localises to TAG-72-expressing colorectal and ovarian adenocarcinoma deposits, and the bound indium-111 …
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
A radioactive imaging agent used to detect colorectal and ovarian cancer that may have spread in the body. It uses an antibody to carry a radioactive label to tumor cells for imaging.
A murine monoclonal antibody against tumour-associated glycoprotein 72 (TAG-72), linked through the pendetide chelator to indium-111. The antibody localises to TAG-72-expressing colorectal and ovarian adenocarcinoma deposits, and the bound indium-111 emits the gamma photons that allow those deposits to be imaged.
Yes, Indium In 111 Satumomab Pendetide is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1743091. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="indium-in-111-satumomab-pendetide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/indium-in-111-satumomab-pendetide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/indium-in-111-satumomab-pendetide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/indium-in-111-satumomab-pendetide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="indium-in-111-satumomab-pendetide"></drugfyi-drug>